EGFR is abnormally and heterogeneously expressed in breast cancers (Nuciforo et al., 2015), and identifying factors that can delineate patient subsets for more effective therapies is of significant clinical interest (Carey et al., 2012, Masuda et al., 2012). This evidence concerns the gene EGFR and breast carcinoma.